FDA Sets Timeline for BLUJEPA Drug Patent Extension
Published Date: 2/13/2026
Notice
Summary
The FDA has officially set the review period for BLUJEPA, a human drug, which helps the company extend its patent protection. This means the drug maker could get more time to exclusively sell BLUJEPA, potentially affecting competition and profits. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by April 14 or August 12, 2026.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets Patent Review Period
The FDA determined BLUJEPA's regulatory review period is 4,948 days total — 4,705 days in the testing phase and 243 days in the approval phase. Key dates are: IND effective September 9, 2011; NDA submitted July 26, 2024; and NDA approved March 25, 2025. The applicant is seeking 5 years of patent extension, and FDA's determination establishes the maximum potential length of a patent extension for BLUJEPA.
Opportunity to Challenge Dates
Anyone who believes the published dates are wrong may ask FDA for a redetermination by April 14, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 12, 2026, following the procedural rules cited in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in